Skip to main content
Equibles
ARTV logo

ARTV · Artiva Biotherapeutics, Inc. · Metrics

Track ARTV — free

Use ARTV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARTV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.56 +0.67 (+11.38%)
Russell 2000 member Rebalance outlook locked
Market Cap
$315.83M
Shares
48.89M
Volume · Oct 20 446K Avg daily vol (3M) 406.59K

ARTV metrics

69 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.89
Market cap
$315.83M

Price action

20 metrics
Price change (1W)
-13.0%
Price change (30D)
-24.8%
Price change (3M)
-35.6%
Price change (6M)
-56.0%
Price change (YTD)
+37.3%
Price change (1Y)
-2.0%
Trailing year
Price change (5Y)
—
52-week high
$13.39
52-week low
$3.07
Change from 52-week high
-56.0%
Change from 52-week low
+91.9%
Annualized volatility
137.9%
Annualized volatility (3M)
60.4%
Beta
1.9
RSI (14D)
25.2
Price vs SMA 50
-36.1%
Price vs SMA 200
-26.3%
Avg volume (3M)
406,585
Relative volume
1.3
Average dollar volume
$3.69M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
48.89M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.8
reciprocal yield 120.0%
FCF yield
-26.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-31.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-08

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$96.15M
Net income (TTM)
−$90.82M
Trailing 12 months
Diluted EPS (TTM)
$-3.31
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.50
EBITDA per diluted share (TTM)
$-3.40
Net income per diluted share (TTM)
$-3.31
Operating cash flow per diluted share (TTM)
$-2.75
Free cash flow per diluted share (TTM)
$-2.81
Capital expenditures per diluted share (TTM)
$0.06
R&D per diluted share (TTM)
$2.75
Stock compensation per diluted share (TTM)
$0.24
Book value per share
—

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+61.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-26.1%
Return on assets
-24.6%
Debt / equity
0.0
Current ratio
24.2
EBITDA (TTM)
−$93.46M
Free cash flow (TTM)
−$76.91M
Quick ratio
24.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$349.39M
Latest balance sheet
Cash & equivalents
$301.45M
Total assets
$368.63M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$75.23M
Capital expenditures (TTM)
$1.68M
R&D (TTM)
$75.86M
SG&A (TTM)
—
Stock compensation (TTM)
$6.68M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
72
13F filer change QoQ
+32
Institutional ownership
82.6%
Conviction holders (share of 13F filers)
4.2%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+136.6%
Holder tenure
5.7
Price vs estimated holder cost
-2.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.6%

Short interest

3 metrics
Short interest
4.7%
Latest settlement · 3.7 days to cover
Days to cover
3.7d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
$302,577
Insider-sentiment score
66 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1817241 CUSIP 04317A107 13F (30d) 5 filings 5 filers Visit website Investor relations